HAI Africa issues briefing paper on the utilization of TRIPS flexibilities in the EAC Region

12 July 2012

A policy briefing paper produced by Health Action International (HAI) Africa analyzing the use of flexibilities under the Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) has made pertinent observations on the different approaches adopted by countries in the East African region.

While all countries are geared towards maximizing use of these flexibilities within their respective national laws, there are areas where limited use of these flexibilities is undermining access to essential medicines. The paper makes a number of pertinent observations and recommendations on how countries can maximize the use of these flexibilities to promote access to essential medicines.

The five member countries of the East African Community (EAC) have incorporated a number of the TRIPS flexibilities in their domestic laws. In addition, the EAC Intellectual Property (IP) and Health Policy and the EAC IP and Health Protocol make key recommendations which if adopted, would promote public health and enhance access to essential medicines within the EAC.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics